483
Daiichi Sankyo Chemical Pharma Co., Ltd.FDA 483 - Daiichi Sankyo Chemical Pharma Co., Ltd. - July 05, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Daiichi Sankyo Chemical Pharma Co., Ltd. in Iwaki, Fukushima, Japan, a drug substance manufacturer, revealed two significant observations. The firm's equipment cleaning validations were found to be inadequate to support established Dirty Hold Time, Clean Hold Time, and revalidation intervals. Additionally, identity testing for a critical material used in drug substance manufacturing was not conducted at established intervals.
Open in Dashboard
ID · ac6f54ee-0044-499f-8449-64de785b9a75